INMUNOTEK has participated in the commercial exhibition of the annual EAACI congress held in Prague (Czech Republic) on 1-3 July. Although it has also been held in hybrid form and hampered by the mobility restrictions that still exist in many countries, it has had a large number of attendees.
INMUNOTEK featured in CIO Bulletin’s “50 Most Admired Companies to Watch 2022” list after being nominated for its business performance based on innovative and competitive products in the allergy and immunology fields.
INMUNOTEK obtains the CIEGE Seal for excellence in business management for the third consecutive year granted by Informa-ElEconomista. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.
INMUNOTEK has once again been awarded the CEPYME500 seal in its 2021 edition, which recognizes the 500 leading Spanish companies in business growth, both for their results and their ability to generate added value, employment, innovation and international projection. This is the third year that INMUNOTEK has received this distinguished seal.
INMUNOTEK joins the CEOE as an associated member. This organization, which represents and defends the interests of Spanish companies, integrates most of the companies based in Spain, through different sectorial organizations or independently associated.
INMUNOTEK and IDIPAZ (Research Institute of the Hospital Universitario La Paz) have signed an agreement to deepen the mechanisms of action of a new anticancer vaccine developed by INMUNOTEK within the RETOS-Collaboration program with the participation of the Hospital Clínico San Carlos, Universidad Complutense de Madrid and CIB-CSIC.
INMUNOTEK has been present at the annual EAACI congress (European Academy of Allergy and Clinical Immunology) held on July 10-12, for the first time in hybrid form between Krakow and Madrid.
INMUNOTEK has participated in the SPAP (Portuguese Society of Pediatric Allergology) Digital Congress with the presentation “Trained immunity vaccines (TIbV) through mucosa against viral infections: the MV130 model” by Dr. Laura Conejero Hall.
INMUNOTEK has participated in the XLV Congress of the SEICAP (Spanish Society of Clinical Immunology, Allergology and Pediatric Asthma) in the session “Meeting with the Expert” entitled “Mite allergens and their cross-reactivity. From scientific evidence to real practice in pediatric patients”.
Within the 42nd congress of the SEI (Spanish Society of Immunology) INMUNOTEK has organized a satellite symposium on trained immunity-based vaccines (TIbV) that act through mucosa and their potential role against respiratory infections of viral origin.